Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1Lymphoma, Follicular 1Hypertension 1Cardiovascular Diseases 1Cardiotoxicity 1

Interventions

Doxorubicin 15Cyclophosphamide 9Exercise 8Dexrazoxane 8Razoxane 6Carvedilol 6Vincristine 4Trastuzumab 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Echocardiography 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Leucovorin 2Ivabradine 2High-Intensity Interval Training 2Epirubicin 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiotoxicity × Angiotensin-Converting Enzyme Inhibitors × Clear all
NCT04092309 2020-04-03

Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation

University of Athens

Phase NA Unknown
90 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡